OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm

OnabotulinumtoxinA (OnabotA) was approved for treatment of chronic migraine (CM) after publication of PREEMPT trials. Thus, we set out to evaluate the efficacy of OnabotA in a series of patients with CM treated according to the PREEMPT protocol. In May 2012 we began to offer OnabotA to patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedraza, María Isabel, de la Cruz, Carolina, Ruiz, Marina, López-Mesonero, Luis, Martínez, Elena, de Lera, Mercedes, Guerrero, Ángel Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398682/
https://www.ncbi.nlm.nih.gov/pubmed/25897415
http://dx.doi.org/10.1186/s40064-015-0957-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398682/
https://www.ncbi.nlm.nih.gov/pubmed/25897415
http://dx.doi.org/10.1186/s40064-015-0957-z

Ejemplares similares